Gibson Oncology
Gibson Oncology is a privately held company focused on developing novel targeted small molecule compounds for cancer treatment. They are advancing proprietary drug candidates in clinical trials, with a focus on inhibiting topoisomerase I and binding G4 quadruplexes in the cMyc promoter to inhibit cMyc expression. The company is engaged in multiple clinical trials funded by the NIH and collaborates with leading research institutions. Their mission is to develop first-in-class anticancer agents that improve safety and efficacy for difficult-to-treat tumors.
Industries
Nr. of Employees
small (1-50)
Gibson Oncology
Miami, Florida, United States, North America
Products
Investigational small-molecule oncology candidates (dual mechanism)
Investigational small-molecule drug candidates that combine topoisomerase I inhibition with selective binding to G-quadruplex structures in the cMyc promoter to reduce cMyc expression; candidates are undergoing clinical evaluation for brain tumors, other solid tumors, and lymphomas.
LMP744
An indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for homologous recombination deficient cancer cells, studied in brain tumors and other solid tumors.
LMP776
An indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for homologous recombination deficient cancer cells, studied in brain tumors and other solid tumors.
Indotecan (LMP400)
A novel indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression, used in brain tumors including glioblastoma.
LMP 744
An oncology drug in Phase II clinical trials for treating glioblastoma multiforme (GBM) patients who have failed initial drug treatment, and for reducing residual tumor burden in GBM patients after radiation and temozolomide treatment.
LMP 400
An oncology agent that has completed Phase I clinical trials in patients with various tumors and is undergoing preclinical studies for brain tumors, specifically ATRX deficient GBM tumors, to support new clinical studies.
Investigational small-molecule oncology candidates (dual mechanism)
Investigational small-molecule drug candidates that combine topoisomerase I inhibition with selective binding to G-quadruplex structures in the cMyc promoter to reduce cMyc expression; candidates are undergoing clinical evaluation for brain tumors, other solid tumors, and lymphomas.
LMP744
An indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for homologous recombination deficient cancer cells, studied in brain tumors and other solid tumors.
LMP776
An indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for homologous recombination deficient cancer cells, studied in brain tumors and other solid tumors.
Indotecan (LMP400)
A novel indenoisoquinoline non-camptothecin topoisomerase I inhibitor selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression, used in brain tumors including glioblastoma.
LMP 744
An oncology drug in Phase II clinical trials for treating glioblastoma multiforme (GBM) patients who have failed initial drug treatment, and for reducing residual tumor burden in GBM patients after radiation and temozolomide treatment.
LMP 400
An oncology agent that has completed Phase I clinical trials in patients with various tumors and is undergoing preclinical studies for brain tumors, specifically ATRX deficient GBM tumors, to support new clinical studies.
Services
Clinical development and coordination of investigational small-molecule oncology compounds through early-phase trials, including collaboration with government-funded research programs.
Clinical development and coordination of investigational small-molecule oncology compounds through early-phase trials, including collaboration with government-funded research programs.
Expertise Areas
- Clinical trial management for oncology
- Oncology small-molecule drug discovery
- Translational research and academic partnerships
- Regulatory strategy for orphan oncology indications
Key Technologies
- Small-molecule medicinal chemistry
- Topoisomerase I inhibition
- G-quadruplex targeting in gene promoters
- Clinical trial design and execution
News & Updates
Gibson Oncology received Orphan Drug Designation from the FDA for both Glioblastoma and multiple types of Gliomas.
Gibson Oncology received Orphan Drug Designation from the FDA for both Glioblastoma and multiple types of Gliomas.